Clinical Trials Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Total 271 results

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Recruiting

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
MediBeacon

Completed

A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants

Kidney Diseases | Kidney Injury | Kidney Failure

China
Changzhou Jinyuan Pharmaceutical Manufacturing...
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

Acute Lymphoblastic Leukemia

China
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Recruiting

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Not yet recruiting

A Phase 3 Study of Efficacy and Safety of TLL-018 in CSU Participants

Chronic Spontaneous Urticaria
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

Chronic Spontaneous Urticaria

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
Hangzhou GluBio Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Recruiting

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (TARA)

Rheumatoid Arthritis

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

Mild to Moderate COVID-19

China
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection

COVID-19 Infection

China
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Completed

Study of WPV01 in Healthy Subjects

Healthy Participants

China
Hangzhou Zenshine Pharmaceuticals Co., Ltd.

Terminated

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Non-hodgkin Lymphoma

United States
Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Not yet recruiting

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Completed

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Psoriasis | Atopic Dermatitis

United States
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Completed

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

Carcinoma，Non-Small-Cell Lung

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Unknown

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

B-cell Lymphoma

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Contrast-induced Acute Kidney Injury

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

Pancreatic Cancer | Advanced Solid Tumor | Gastric Cancer (GC) | Gastroesophageal Junction (GEJ) Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis

Invasive Aspergillosis | Invasive Candidiasis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China

Clinical Trials Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations